Clinical and dynamic circulating cytokines profile features of long-term progression-free survival benefit to immune checkpoint inhibitors in advanced non–small cell lung cancer
Distinct clinical characteristics, including TMB, PD-L1, pathologic subtypes, LIPI score, number of organs involved, metastatic sites, and dynamic circulating cytokines profile features, can distinguish NSCLC patients achieving LTPFS from those with STPFS following first-line ICIs monotherapy.
Authors
- Chong‐Rui Xu (ORCID: https://orcid.org/0000-0002-3474-2809)
- Zhihong Chen (ORCID: https://orcid.org/0000-0002-9749-2501)
- Xue Fan (ORCID: https://orcid.org/0000-0001-6406-7245)
- Qing Zhou (ORCID: https://orcid.org/0000-0002-0922-9915)
- Jia‐Yi Deng
- Ming Gao (ORCID: https://orcid.org/0000-0003-4602-4393)
- Mingyi Yang (ORCID: https://orcid.org/0000-0003-4347-6239)
- Xiaorong Yang (ORCID: https://orcid.org/0009-0004-1275-304X)
- Wei‐Chi Luo
- Hong-Hong Yan
Institutions
- First Affiliated Hospital of Guangzhou Medical University (CN)
- South China University of Technology (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- Cancer Immunology Immunotherapy
- Published
- 2025-04-17
- DOI
- https://doi.org/10.1007/s00262-025-03984-7
- Citations
- 2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- National Natural Science Foundation of China
- Ministry of Education, India